Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemigatinib + retifanlimab
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of two targeted anticancer agents: **pemigatinib**, a selective small molecule inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3, and **retifanlimab**, a monoclonal antibody that blocks programmed cell death protein 1 (PD-1). This combination is being investigated in clinical trials for the treatment of advanced or metastatic solid tumors, including dedifferentiated liposarcoma and other malignancies. The rationale is to combine FGFR inhibition, which blocks a pathway often dysregulated in cancers, with immune checkpoint inhibition, which enhances antitumor immune responses[1][2][4][7].
- Brand names
- Pemazyre
- Other names
- pemigatinib + retifanlimab
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on pemigatinib + retifanlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemigatinib + retifanlimab.